triamcinolone acetonide injectable suspension/nystatin (Rx)

Brand and Other Names:MyCo-Triacet II, Mycolog II, more...Mycogen II, Mytrex, Tri-Statin II
  • Print
Sections

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

triamcinolone/nystatin

topical cream/ointment

  • (0.1%/100,000units)/g

Cutaneous Candidiasis

Apply cream/ointment BID; discontinue therapy when infection is under control or if symptoms persist for >25 days

Dosage Forms & Strengths

triamcinolone/nystatin

topical cream/ointment

  • (0.1%/100,000units)/g

Cutaneous Candidiasis

As adults; apply cream/ointment BID; discontinue therapy when infection is under control or if symptoms persist for >25 days

Next:

Interactions

Interaction Checker

and triamcinolone acetonide injectable suspension/nystatin

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Due to system maintenance, the drug interactions feature you are attempting to access is temporarily unavailable. Please try again later.
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Blistering

            Burning

            Dryness

            Acniform eruptions

            Excessive discoloring of the skin

            Excessive hair growth (especially on face)

            Hair loss (especially on scalp)

            Inflammation around the mouth

            Inflammation of hair follicles

            Irritation

            Itching

            Peeling

            Prickly heat

            Striae

            Secondary infection

            Skin inflammation

            Softening of the skin

            Stretch marks

            Stretching or thinning of the skin

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Cautions

            For topical use only

            Not for ophthalmic use

            Avoid contact with eyes

            Patient should report any signs of adverse reactions

            Systemic absorption of topical corticosteroids has produced reversible hypothalmic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients

            Conditions that augment systemic absorption include application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings

            Patients receiving a large dose of any potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis; if HPA axis suppression or elevation of body temperature occurs, make attempt to withdraw drug, reduce frequency of application, or substitute for less potent steroid

            Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of drug; infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids

            Children may absorb proportionally larger amounts of topical corticosteroids and thus may be more susceptible to systemic toxicity

            If irritation or hypersensitivity develops with combination of nystatin and triamcinolone acetonide, discontinue treatment and institute appropriate therapy

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: unknown

            Lactation: unknown if excreted in breast milk

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Triamcinolone potency

            Medium

            Very-high: clobetasol, diflorasone diacetate ointment 0.05%, halobetasol

            High: betamethasone dipropionate 0.05%, amcinonide, fluocinonide, desoximetasone, mometasone, diflorasone emollient 0.05%, halcinonide

            Medium: triamcinolone, betamethasone valerate 0.1%, fluticasone, flurandrenolide, fluocinolone 0.025%, hydrocortisone

            Mild: hydrocortisone 0.5, 1, 2.5% base, desonide, alclometasone

            Mechanism of Action

            Nystatin: Antifungal activity

            Triamcinolone: Corticosteroid; elicits antipruritic and anti-inflammatory effects

            Previous
            Next:

            Images

            No images available for this drug.
            Previous
            Next:

            Patient Handout

            A Patient Handout is not currently available for this monograph.
            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.